| P50 | author | Hans-Georg Kräusslich | Q1576991 |
| | Dirk Jochmans | Q56450393 |
| | Barbara Müller | Q67532985 |
| P2093 | author name string | Maria Anders | |
| | Liesbeth Smeulders | |
| | Günter Kraus | |
| | Inge Keuleers | |
| P2860 | cites work | Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates | Q24812175 |
| | Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 |
| | Non-viral cellular substrates for human immunodeficiency virus type 1 protease | Q28264830 |
| | Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol | Q28469069 |
| | ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia | Q28469175 |
| | Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 |
| | Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli | Q33703756 |
| | Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein | Q33750683 |
| | Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. | Q33785282 |
| | HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation | Q33948995 |
| | Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy | Q33962223 |
| | Enzymatic detection of protein translocation | Q34428441 |
| | Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). | Q35005228 |
| | Apoptosis as an HIV strategy to escape immune attack | Q35136008 |
| | The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth | Q35888601 |
| | Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo | Q35914355 |
| | Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase | Q36297904 |
| | Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy | Q36499290 |
| | The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. | Q36636632 |
| | Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery | Q36758566 |
| | HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 |
| | Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production | Q36797953 |
| | HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells | Q36901499 |
| | Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor | Q37072072 |
| | Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy | Q37200979 |
| | Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 |
| | Gene expression and cell fusion analyzed by lacZ complementation in mammalian cells | Q37239978 |
| | Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2 | Q37356313 |
| | The challenge of finding a cure for HIV infection | Q37407598 |
| | Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity | Q37480211 |
| | IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection | Q37683631 |
| | Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 |
| | Alpha complementation of LacZ in mammalian cells | Q39715815 |
| | MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells | Q39959363 |
| | Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative | Q39991984 |
| | The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. | Q40042979 |
| | Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation | Q40049266 |
| | A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors | Q40206176 |
| | Double-labelled HIV-1 particles for study of virus-cell interaction. | Q40209637 |
| | Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor | Q40367975 |
| | Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles | Q41564861 |
| | HIV protease cleaves poly(A)-binding protein. | Q42533713 |
| | Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers | Q42738742 |
| | Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection | Q43418787 |
| | Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression | Q43655245 |
| | Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy | Q43807839 |
| | Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability | Q45001878 |
| | Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation | Q45218379 |
| | A sensitive method for the detection of beta-galactosidase in transfected mammalian cells | Q45349737 |
| | Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. | Q45860281 |
| | A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility | Q46295068 |
| | Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase | Q46964863 |
| | Mutation of the major 5' splice site renders a CMV-driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing. | Q47822116 |
| | Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 |
| | In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. | Q52050894 |
| | HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection | Q58198364 |
| | RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms | Q59663057 |
| | Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy | Q73162446 |
| | Cell killing by HIV-1 protease | Q78346287 |
| | Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man | Q94702271 |
| P304 | page(s) | 89 | |
| P577 | publication date | 2010-10-15 | |
| P1433 | published in | Retrovirology | Q15793508 |
| P1476 | title | Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease | |
| P478 | volume | 7 | |